Current diagnosis and treatment of CIN II

DOI

https://dx.doi.org/10.18565/aig.2020.1suppl.18-25

Krasnopol’skii V.I., Zarochentseva N.V., Ashrafyan L.A., Kiselev V.I., Dzhidzhikhiya L.K., Baranov I.I., Dzhavakhishvili M.G.
1) Moscow Regional Research Institute of Obstetrics and Gynecology of Minzdrav of Moscow Region, Russia; 2) V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia, Moscow

This review article is aimed at raising the awareness of obstetrician-gynecologists about the appropriateness of conservative management of patients aged under 25, primary prevention of HPV-associated cervical diseases and cervical cancer, and the possibility of reducing the risk of recurrence after curative treatment. The article summarizes research evidence from relevant international and domestic scientific literature available at PubMed and published over the past 10 years. The authors analyze current literature on the conservative management of young patients with cervical intraepithelial neoplasia II (CIN II) and present data on the prevalence, diagnosis, and features of the course of CIN II in women aged under 25, and the role of human papillomavirus in cancer development. The review addresses the importance of primary prevention of cervical cancer, the feasibility of conservative treatment of young patients with CIN II, and the possibility of reducing the risk of recurrence after curative treatment. This review article should be helpful for obstetrician-gynecologists in increasing their knowledge on the primary prevention of cervical cancer, and strategy for conservative management of young patients with CIN II to preserve their reproductive potential.

human papillomavirus

human papillomavirus infection

cervical intraepithelial neoplasia II (CIN II)

cervical cancer

Full text (in Russian)

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68(6): 394-424. https://dx.doi.org/10.3322/caac.21492.
International Classification of Diseases 11th Revision. Available at: https://icd. who.int
Kurman R.J., Carcangiu M.L., Herrington C.S., Young R.H. WHO Classification of tumours of female reproductive organs. Lyon: IARC; 2014.
Wright T.C. Jr, Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Lower Genit. Tract Dis. 2007; 11(4): 201-22. https://dx.doi.org/10.1097/LGT.0b013e3181585870.
De Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B. et al.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11): 1048-56. https://dx.doi.org/10.1016/S1470-2045(10)70230-8.
Oakeshott P., Aghaizu A., Reid F., Howell-Jones R., Hay P.E., Sadiq S.T. et al. Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. BMJ 2012; 344: e4168.https://dx.doi.org/10.1136/bmj.e4168.
Madeleine M.M., Anttila T., Schwartz S.M., Saikku P., Leinonen M., Carter J.J. et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int. J. Cancer. 2007; 120(3): 650-5. https://dx.doi.org/10.1002/ijc.22325.
Smith J.S., Herrero R., Bosetti C., Muñoz N., Bosch F.X., Eluf-Neto J. et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J. Natl. Cancer Inst. 2002; 94(21): 1604-13. https://dx.doi.org/10.1093/jnci/94.21.1604.
Савельева Г.М., Сухих Г.Т., Серов В.Н., Радзинский В.Е., Манухин И.Б., ред. Гинекология. Национальное руководство. М.: ГЭОТАР-Медиа; 2017. 989 с. [Savel’eva G.M., Sukhikh G.T., Serov V.N., Radzinskii V.E., Manukhin I.B., eds. Ginekologiya. Natsional’noe rukovodstvo. Moscow: GEOTAR-Media; 2017. 989 p. (in Russian)].
Padmini C.P., Indira N., Chaitra R., Das P., Girish B.C., Nanda K.M. Cytological and colposcopic evaluation of unhealthy cervix. J. Evid. Based Med. Healthc. 2015; 2: 6920-7. https://dx.doi.org/10.18410/jebmh/2015/925.
Schmidt D. Modern biomarkers for precancerous lesions of the uterine cervix: Histological-cytological correlation and use. Pathologe. 2016; 37(6): 534-41. https://dx.doi.org/10.1007/s00292-016-0231-3.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology.Obstet. Gynecol. 2008; 112(6): 1419-44. https://dx.doi.org/10.1097/AOG.0b013e318192497c.
Краснопольский В.И., Короленкова Л.И., Зароченцева Н.В., Жордания К.И., Щукина Н.А. Облигатные формы предрака и инвазивный рак шейки матки. Руководство для врачей. Краснопольский В.И., ред. М.: СИМК; 2017. 160 с. [Krasnopol’skii V.I., Korolenkova L.I., Zarochentseva N.V., Zhordaniya K.I., Shchukina N.A. Obligatnye formy predraka i invazivnyi rak sheiki matki. Rukovodstvo dlya vrachei. Krasnopol’skii V.I., ed. Moscow: SIMK; 2017. 160 p. (in Russian)].
Schiffman M., Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch. Pathol. Lab. Med. 2003; 127(8): 946-9.https://dx.doi.org/10.1043/1543-2165(2003)127<946:FTDFTA>2.0.CO;2.
Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U. et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer. 2001; 92(2): 276-84.https://dx.doi.org/10.1002/ijc.1174.
Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am. J. Clin. Pathol. 2012; 137(4): 516-42. https://dx.doi.org/10.1309/AJCPTGD94EVRSJCG.
Miyamoto S., Hasegawa J., Morioka M., Hirota Y., Kushima M., Sekizawa A. The association between p16 and Ki-67 immunohistostaining and the progression of cervical intraepithelial neoplasia grade 2. Int. J. Gynaecol. Obstet. 2016; 134(1): 45-8. https://dx.doi.org/10.1016/j.ijgo.2015.12.005.
Demarco M., Lorey T.S., Fetterman B., Cheung L.C., Guido R.S., Wentzensen N. et al. Risks of CIN 2+, CIN 3+, and cancer by cytology and human papillomavirus status: the foundation of risk-based cervical screening guidelines. J. Low Genit. Tract Dis. 2017; 21(4): 261-7. https://dx.doi.org/10.1097/LGT.0000000000000343.
NHSCSP Guidelines no.20 (3rd edition). Home/Medical Professionals/NHSCSP Guidelines. Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening Programme Published March 2016. Available at: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=370275
Bentley J. Colposcopic management of abnormal cervical cytology and histology. J. Obstet. Gynaecol. Can. 2012; 34(12): 1188-202. https://dx.doi.org/10.1016/S1701-2163(16)35468-8.
Moscicki A.B., Ma Y., Wibbelsman C., Darragh T.M., Powers A., Farhat S., Shiboski S. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet. Gynecol. 2010; 116(6): 1373-80. https://dx.doi.org/10.1097/AOG.0b013e3181fe777f.
McAllum B., Sykes P.H.H., Sadler L., Macnab H., Simcock B.J., Mekhail A.K. Is the treatment of CIN 2 always necessary in women under 25 years old? Am. J. Obstet. Gynecol. 2011; 205(5): 478. e1-7. https://dx.doi.org/10.1016/j.ajog.2011.06.069.
Loopik D.L., Bekkers R.L.M., Massuger L.F.A.G., Melchers W.J.G., Siebers A.G., Bentley J. Justifying conservative management of CIN2 in women younger than 25 years - A population-based study. Gynecol. Oncol. 2019; 152(1): 82-6. https://dx.doi.org/10.1016/j.ygyno.2018.10.038.
Tainio K., Athanasiou A., Tikkinen K.A.O., Aaltonen R., Cárdenas J., Hernándes. et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018; 360: k499. https://dx.doi.org/10.1136/bmj.k499.
Sasieni P., Castanon J., Parkin D.M. How many cancers are prevented by treatment of screen-detected disease in young women? Int. J. Cancer. 2009; 124: 461-4. https://dx.doi.org/10.1002/ijc.23922.
Castle P.E., Schiffman M., Wheeler C.M., Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet. Gynecol. 2009; 113(1): 18-25. https://dx.doi.org/10.1097/AOG.0b013e31818f5008.
Discacciati M.G., de Souza C.A., d’Otavianno M.G., Ângelo-Andrade L.A., Westin M.C., Rabelo-Santos S.H., Zeferino L.C. Outcome of expectant management of cervical intraepithelial neoplasia grade 2 in women followed for 12 months. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 155(2): 204-8. https://dx.doi.org/10.1016/j.ejogrb.2010.12.002.
Fuchs K., Weitzen S., Wu L., Phipps M.G., Boardman L.A. Management of cervical intraepithelial neoplasia 2 in adolescent and young women. J. Pediatr. Adolesc. Gynecol. 2007; 20(5): 269-74. https://dx.doi.org/10.1016/j.jpag.2007.04.012.
Moore K., Cofer A., Elliot L., Lanneau G., Walker J., Gold M.A. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am. J. Obstet. Gynecol. 2007; 197(2): 141. e1-6. https://dx.doi.org/10.1016/j.ajog.2007.03.029.
Guedes A.C., Zeferino L.C., Syrjänen K.J., Brenna S.M.F. Short-term outcome of cervical intraepithelial neoplasia grade 2: considerations for management strategies and reproducibility of diagnosis. Anticancer Res. 2010; 30(6): 2319-23.
Kyrgiou M., Mitra A., Arbyn M., Stasinou S.M., Martin-Hirsch P., Bennett P., Paraskevaidis E. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ. 2014; 349: g6192. https://dx.doi.org/10.1136/bmj.g6192.
Wilkinson T.M., Sykes P.H., Simcock B., Petrich S. Recurrence of high-grade cervical abnormalities following conservative management of cervical intraepithelial neoplasia grade 2. Am. J. Obstet. Gynecol. 2015; 212(6): 769. e1-7. https://dx.doi.org/10.1016/j.ajog.2015.01.010.
Castanon A., Brocklehurst P., Evans H., Peebles D., Singh N., Walker P. et al. Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study. BMJ. 2012; 345: e5174. https://dx.doi.org/10.1136/bmj.e5174.
Janevic T., Stein C.R., Savitz D.A., Kaufman J.S., Mason S.M., Herring A.H. Neighborhood deprivation and adverse birth outcomes among diverse ethnic groups. Ann. Epidemiol. 2010; 20(6): 445-51. https://dx.doi.org/10.1016/j.annepidem.2010.02.010.
Perkins R.B., Jorgensen J.R., McCoy M.E., Bak S.M., Battaglia T.A., Freund K.M. Adherence to conservative management recommendations for abnormal PAP test results in adolescents. Obstet. Gynecol. 2012; 119(6): 1157-63.https://dx.doi.org/10.1097/AOG.0b013e31824e9f2f.
Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M. et al. 2012 updated consensus guide- lines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet. Gynecol. 2013; 121(4): 829-46. https://dx.doi.org/10.1097/AOG.0b013e3182883a34.
Paraskevaidis E., Arbyn M., Sotiriadis A., Diakomanolis E., Martin-Hirsch P., Koliopoulos G. et al. The role of DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat. Rev. 2004; 30(2): 205-11. https://dx.doi.org/10.1016/j.ctrv.2003.07.008.
Клинические рекомендации «Доброкачественные и предраковые заболевания шейки матки с позиции профилактики рака». М.; 2017. 55 с. [Klinicheskie rekomendatsii «Dobrokachestvennye i predrakovye zabolevaniya sheiki matki s pozitsii profilaktiki raka». M.oscow 2017. 55 p. (in Russian)].
Zhu J., Li Y., Guan C., Chen Z. Anti-proliferative and pro-apoptotic effects of 3,3’- diindolylmethane in human cervical cancer cells. Oncol. Rep. 2012; 28(3): 1063-8. https://dx.doi.org/10.3892/or.2012.1877.
Sales K.J., Katz A.A. Inflammatory pathways in cervical cancer - the UCT contribution. South Afr. Med. J. 2012; 102(6): 493-6.https://dx.doi.org/10.7196/samj.5532.
Wu T.Y., Khor T.O., Su Z.Y., Saw C.L., Shu L., Cheung K.L. et al. Epigenetic modifications of Nrf2 by 3,3’-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors. AAPS J. 2013; 15(3): 864-74. https://dx.doi.org/10.1208/s12248-013-9493-3.
Сухих Г.Т., Ашрафян Л.А., Киселев В.И., Аполихина И.А., Мальцева Л.И., Сутурина Л.В., Селиванов С.П., Леонидова Т.Н., Цхай В.Б., Радзинский В.Е., Ордиянц И.М., Бебнева Т.Н., Евтушенко И.Д., Удут В.В., Кулагина Н.В., Баранов А.Н., Хасанов Р.Ш., Гурьева В.А., Шамина И.В., Карахалис Л.Ю., Муйжнек Е.Л. Исследование эффективности и безопасности препарата на основе дииндолилметана у пациенток с цервикальной интраэпителиальной неоплазией (CIN 1–2). Акушерство и гинекология. 2018; 9: 991-8. [Sukhikh G.T., Ashrafyan L.A., Kiselev V.I., Apolikhina I.A., Maltseva L.I., Suturina L.V., Selivanov S.P., Leonidova T.N., Tskhai V.B., Radzinsky V.E., Ordiyants I.M., Bebneva T.N., Evtushenko I.D., Udut V.V., Kulagina N.V., Baranov A.N., Khasanov R.Sh., Guryeva V.A., Shamina I.V., Karakhalis L.Yu., Muyzhnek E.L. Investigation of the efficacy and safety of a diindolylmethane-based drug in patients with cervical intraepithelial neoplasia grades 1-2 (CIN 1-2). Obstetrics and Gynecology/Akusherstvo i ginekologiya. 2018; (9): 991-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2018.9.91-98.
Киселев В.И., Ашрафян Л.А., Друх В.М., Муйжнек Е.Л., Кузнецов И.Н., Пчелинцева О.И., Андрианова Е.А., Барановский П.М. Клиническое исследование по изучению эффективности суппозиториев «Цервикон-ДИМ» при лечении цервикальной интраэпителиальной неоплазии легкой и средней степени. Вестник Российского научного центра рентгенорадиологии Минздрава России. 2014; 14-3: 6. [Kiselev V.I., Ashrafyan L.A., Drukh V.M, Muyzhnek E.L., Kuznetsov I.N., Pchelintseva O.I., Andrianova E.A, Baranovskiy P.M.Efficacy of the novel pharmaceutical composition in suppository form comprising DIM in patients with grade 1-2 cervical intraepithelial neoplasia (CIN 1-2). Vestnik Rossiiskogo nauchnogo tsentra rentgenoradiologii Minzdrava Rossii. 2014; 14-3: 6. (in Russian)].
Ashrafian L., Sukhikh G., Kiselev V., Paltsev M., Drukh V., Kuznetsov I., Muyzhnek E., Apolikhina I., Andrianova E. Double-blind randomized placebocontrolled multicenter clinical trial (phase IIa) on diindolylmethane’s efficacy and safety in the treatment of CIN: implications for cervical cancer prevention. EPMA J. 2015 Dec 21;6:25. https://dx.doi.org/10.1186/s13167-015-0048-9.
Food and Drug Administration (FDA). Vaccines, blood and biologics. FDA,; 2017. Available at: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts
Drolet M., Benard E., Boily M.C., Ali H., Baandrup L., Bauer H. et al. Populationlevel impact and herd effects following human papillomavirus vac- cination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 2015; 15(5): 565-80. https://dx.doi.org/10.1016/S1473-3099(14)71073-4.
Joura E.A., Garland S.M., Paavonen J., Ferris D.G., Perez G., Ault K.A. et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012; 344: e1401. https://dx.doi.org/10.1136/bmj.e1401.
Kang W.D., Choi H.S., Kim S.M. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision pro cedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol. Oncol. 2013; 130(2): 264-8. https://dx.doi.org/10.1016/j.ygyno.2013.04.050.
Ghelardi A., Parazzini F., Martella F., Pieralli A., Bay P., Tonetti A. et al. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol. Oncol. 2018; 151(2): 229-34. https://dx.doi.org/10.1016/j.ygyno.2018.08.033.

Received 19.12.2019

Accepted 30.12.2019

Vladislav I. Krasnopolsky, academician of the Russian Academy of Sciences, doctor of medical sciences, professor, president of GBUZ MO
Moscow Regional Research Institute of Obstetrics and Gynecology. ORCID ID: orcid.org/0000-0001-7041-9024.
101000 Russia, Moscow, ul. Pokrovka, d.22A.
Nina V. Zarochentseva, MD, professor of the Russian Academy of Sciences, Deputy Director for Research, Moscow Regional Research Institute of Obstetrics and Gynecology. ORCID ID: orcid.org/0000-0001-6155-788X, ninazar11@mail.ru
101000 Russia, Moscow, ul. Pokrovka, d.22A.
Lev A. Ashrafyan, academician of the Russian Academy of Sciences, MD, professor, direktor of the Institute of Oncogynecology and Mammology, FSBI National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Acad. V. I. Kulakova “of the Ministry of Health of the Russian Federation.
117997, Moscow, st. Academician Oparin, d. 4.
Vsevolod I. Kiselev, Corresponding Member of the Russian Academy of Medical Sciences and RAS, Doctor of Biological Sciences, Professor, Deputy Director for Research at the Institute of Oncogynecology and Mammology, Federal State Budgetary Institution National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Acad. V. I. Kulakova »of the Ministry of Health of the Russian Federation, ORCID ID: orcid.org/0000-0002-4721-3420
117997 Russia, Moscow, ul. Academician Oparin, d. 4.
Lela K. Dzhidzhikhiya, PhD, Researcher at the Department of Gynecological Endocrinology GBUZ MO Moscow Regional Research Institute of Obstetrics and Gynecology. ORCID ID: orcid.org/0000-0002-2853-0957, lel3311@yandex.ru
101000 Russia, Moscow, ul. Pokrovka, d.22A.
Igor I. Baranov, MD, professor, head of the organizational and methodological department of the scientific and organizational support service of the FSBI “V.I. Kulakov Scientific Center for Obstetrics, Gynecology and Perinatology”, Scientific Secretary of the Russian Society of Obstetricians and Gynecologists,
ORCID ID: orcid.org/0000-0002-9813-2823.
117997 Russia, Moscow, ul. Academician Oparin, d. 4.
Mariami G. Javakhishvili, graduate student of the outpatient department of GBUZ MO Moscow Regional Research Institute of Obstetrics and Gynecology.
ORCID ID: orcid.org/0000-0002-23852850
101000 Roosia, Moscow, ul. Pokrovka, d.22A.

For citation: Krasnopol’skii V.I., Zarochentseva N.V., Ashrafyan L.A., Kiselev V.I., Dzhidzhikhiya L.K., Baranov I.I., Dzhavakhishvili M.G. Current diagnosis and treatment of CIN II.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 1(Suppl): 18-25 (in Russian)
https://dx.doi.org/10.18565/aig.2020.1suppl.18-25

Current diagnosis and treatment of CIN II

Krasnopol’skii V.I., Zarochentseva N.V., Ashrafyan L.A., Kiselev V.I., Dzhidzhikhiya L.K., Baranov I.I., Dzhavakhishvili M.G.

Keywords

References

About the Authors

Similar Articles